Another big TK inhibitor deal

Bayer & Regeneron.
$75M upfront.
$245M in potential downstream payments. ($40M for phase 3 initiation, $70M for marketing approval, $135M in sales milestones beginning at $200M in annual sales.)
Shared development expenses.
Shared ex-US profits.
For ex-US rights to a phase II compound targeting an indication that there's already one approved remedy (Macugen) and another pending (Lucentis.)